Kineta Price to Book Ratio 2014-2024 | KANT
Historical price to book ratio values for Kineta (KANT) over the last 10 years. The current price to book ratio for Kineta as of September 19, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Kineta Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2024-09-18 |
0.57 |
|
0.00 |
| 2024-06-30 |
0.53 |
$-0.65 |
-0.82 |
| 2024-03-31 |
0.53 |
$-0.55 |
-0.96 |
| 2023-12-31 |
3.63 |
$0.29 |
12.34 |
| 2023-09-30 |
3.40 |
$0.28 |
12.02 |
| 2023-06-30 |
2.58 |
$0.78 |
3.30 |
| 2023-03-31 |
3.31 |
$-0.01 |
-501.52 |
| 2022-12-31 |
6.35 |
$0.55 |
11.56 |
| 2022-09-30 |
1.57 |
$3.53 |
0.44 |
| 2022-06-30 |
1.82 |
$5.12 |
0.36 |
| 2022-03-31 |
1.50 |
$7.55 |
0.20 |
| 2021-12-31 |
2.96 |
$-2.57 |
-1.15 |
| 2021-09-30 |
10.32 |
$22.04 |
0.47 |
| 2021-06-30 |
11.65 |
$27.98 |
0.42 |
| 2021-03-31 |
18.10 |
$33.59 |
0.54 |
| 2020-12-31 |
17.00 |
$38.58 |
0.44 |
| 2020-09-30 |
22.00 |
$99.48 |
0.22 |
| 2020-06-30 |
27.40 |
$120.60 |
0.23 |
| 2020-03-31 |
22.80 |
$142.62 |
0.16 |
| 2019-12-31 |
45.60 |
$-7.12 |
-6.40 |
| 2019-09-30 |
16.90 |
$191.95 |
0.09 |
| 2019-06-30 |
19.52 |
$224.55 |
0.09 |
| 2019-03-31 |
25.20 |
$276.85 |
0.09 |
| 2018-12-31 |
64.80 |
$314.97 |
0.21 |
| 2018-09-30 |
48.20 |
$148.39 |
0.32 |
| 2018-06-30 |
55.80 |
$215.21 |
0.26 |
| 2018-03-31 |
95.00 |
$244.05 |
0.39 |
| 2017-12-31 |
116.60 |
$279.82 |
0.42 |
| 2017-09-30 |
42.00 |
$213.56 |
0.20 |
| 2017-06-30 |
93.60 |
$285.83 |
0.33 |
| 2017-03-31 |
156.40 |
$375.24 |
0.42 |
| 2016-12-31 |
245.20 |
$456.00 |
0.54 |
| 2016-09-30 |
311.80 |
$504.81 |
0.62 |
| 2016-06-30 |
242.60 |
$223.86 |
1.08 |
| 2016-03-31 |
192.80 |
$289.04 |
0.67 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
